PIPC submitted a comment letter to the Washington Prescription Drug Affordability Board (PDAB) highlighting the concerns of patients and people with disabilities related to the PDAB’s potential use of discriminatory cost effectiveness analyses.
|
PIPC recently sent a letter to Senator Bill Ferguson and Delegate Adrianne Jones urging Maryland's Legislative Policy Committee to reject the Prescription Drug Affordability Board's (PDAB) proposed Upper Payment Limit (UPL) plan.
PIPC recently submitted comments to the Oregon Prescription Drug Affordability Board (PDAB) to avoid using studies that rely on discriminatory metrics such as the Quality-Adjusted Life Year (QALY) that have detrimental implications for access to needed care and treatment. The letter also encourages the Oregon PDAB to include patients and people with disabilities throughout its decision-making process.
The Partnership to Improve Patient Care (PIPC) recently submitted comments on the Institute for Clinical and Economic Review's (ICER) assessment of treatments for for Epstein-Barr virus positive post-transplant lymphoproliferative disease.
The Centers for Medicare and Medicaid Services (CMS) recently published final guidance governing its implementation of the Medicare Drug Price Negotiation Program for 2026-2027. The Partnership to Improve Patient Care (PIPC) shares the goal of advancing affordability of health care for all patients and people with disabilities.
38 organizations representing patients and people with disabilities strongly urged the Maryland Prescription Drug Affordability Board (PDAB) to prioritize the perspectives of people whose care may be impacted by your decisions as it works to finalize a Plan of Action for Implementing the Process for Setting Upper Payment Limits
The Centers for Medicare and Medicaid Services (CMS) recently announced the prices for the first 10 drugs targeted by the Medicare Drug Price Negotiation Program. The Partnership to Improve Patient Care (PIPC) shares the goal of advancing affordability of health care for all patients and people with disabilities. It is critical that individuals can both afford and access the treatments prescribed by their physicians.
In a letter to the Institute for Clinical and Economic Review, PIPC submitted comments on ICER's assessment of treatments for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
On August 2, the Partnership to Improve Patient Care (PIPC) submitted a comment letter to Reps. Diana DeGette (D-CO) and Larry Bucshon (R-IN) on their recent request for information (RFI) on advancing 21st Century Cures policies.
Nearly 60 organizations and advocates representing the patient and disability communities joined PIPC's comment letter on the Centers for Medicare and Medicaid Services' (CMS) guidance implementing the Medicare Drug Price Negotiation Program.
|
Topics
All
Archives
October 2024
|
